Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 39
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Specific hippocampal interneurons shape consolidation of recognition memory

  • Oliveira da Cruz, Jose F.
  • Busquets Garcia, Arnau, 1985-
  • Zhao, Zhe
  • Varilh, Marjorie
  • Lavanco, Gianluca
  • Robin, Laurie
  • Cannich, Astrid
  • Julio-Kalajzić, Francisca
  • Lesté-Lasserre, Thierry
  • Maître, Marlène
  • Drago, Filippo
  • Marsicano, Giovanni
  • Soria-Gómez, Edgar
A complex array of inhibitory interneurons tightly controls hippocampal activity, but how such diversity specifically affects memory processes is not well understood. We find that a small subclass of type 1 cannabinoid receptor (CB1R)-expressing hippocampal interneurons determines episodic-like memory consolidation by linking dopamine D1 receptor (D1R) signaling to GABAergic transmission. Mice lacking CB1Rs in D1-positive cells (D1-CB1-KO) display impairment in long-term, but not short-term, novel object recognition memory (NOR). Re-expression of CB1Rs in hippocampal D1R-positive cells rescues this NOR deficit. Learning induces an enhancement of in vivo hippocampal long-term potentiation (LTP), which is absent in mutant mice. CB1R-mediated NOR and the associated LTP facilitation involve local control of GABAergic inhibition in a D1-dependent manner. This study reveals that hippocampal CB1R-/D1R-expressing interneurons control NOR memory, identifying a mechanism linking the diversity of hippocampal interneurons to specific behavioral outcomes., We thank Delphine Gonzales, Nathalie Aubailly, and the personnel of the Animal Facilities of the NeuroCentre Magendie for mouse care. We thank the Biochemistry Platform of Bordeaux NeuroCampus and the members of Marsicano’s lab for useful discussions. This work was funded by INSERM; the European Research Council (Endofood ERC-2010-StG-260515, CannaPreg ERC-2014-PoC-640923, and MiCaBra ERC-2017-AdG-786467 to G.M.); Fondation pour la Recherche Medicale (FRM; DRM20101220445 to G.M. and DT20160435664 to J.F.O.d.C.); the Human Frontiers Science Program, Region Aquitaine, Agence Nationale de la Recherche (ANR; NeuroNutriSens ANR-13-BSV4-0006, ORUPS ANR-16-CE37-0010-01, and CaCoVi ANR-18-CE16-0001-02 to G.M.); BRAIN ANR-10-LABX-0043 (to G.M.); NIH/NIDA (1R21DA037678-01); the European Regional Development Fund; the European Union Horizon 2020 Research and Innovation Program (grant agreement 686009); French State/Agence Nationale de la Recherche/IdEx (ANR-10-IDEX-03-02), Eu-Fp7 (FP7-PEOPLE-2013-IEF-623638), and MINECO/AEI (RYC-2017-21776) (to A.B.-G.); FRM (ARF20140129235 to L.B.); and Ikerbasque (The Basque Foundation for Science) and MINECO (Ministerio de Economía y Competitividad) PGC2018-093990-A-I00 (MICIU/AEI/FEDER, UE) (to E.S.-G.).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Characterization of a preclinical PET insert in a 7 tesla MRI scanner: beyond NEMA testing

  • Gsell, Willy
  • Molinos, Cesar
  • Correcher, Carlos
  • Belderbos, Sarah
  • Wouters, Jens
  • Junge, Sven
  • Heidenreich, Michael
  • Vande Velde, Greetje
  • Rezaei, Ahmadreza
  • Nuyts, Johan
  • Cawthorne, Christopher
  • Cleeren, Frederik
  • Nannan, Lise
  • Deroose, Christophe M.
  • Himmelreich, Uwe
  • González Martínez, Antonio Javier
[EN] This study evaluates the performance of the Bruker positron emission tomograph (PET) insert combined with a BioSpec 70/30 USR magnetic resonance imaging (MRI) scanner using the manufacturer acceptance protocol and the NEMA NU 4-2008 for small animal PET. The PET insert is made of 3 rings of 8 monolithic LYSO crystals (50 x 50 x 10 mm(3)) coupled to silicon photomultipliers (SiPM) arrays, conferring an axial and transaxial FOV of 15 cm and 8 cm. The MRI performance was evaluated with and without the insert for the following radiofrequency noise, magnetic field homogeneity and image quality. For the PET performance, we extended the NEMA protocol featuring system sensitivity, count rates, spatial resolution and image quality to homogeneity and accuracy for quantification using several MRI sequences (RARE, FLASH, EPI and UTE). The PET insert does not show any adverse effect on the MRI performances. The MR field homogeneity is well preserved (Diameter Spherical Volume, for 20 mm of 1.98 +/- 4.78 without and -0.96 +/- 5.16 Hz with the PET insert). The PET insert has no major effect on the radiofrequency field. The signal-to-noise ratio measurements also do not show major differences. Image ghosting is well within the manufacturer specifications (<2.5%) and no RF noise is visible. Maximum sensitivity of the PET insert is 11.0% at the center of the FOV even with simultaneous acquisition of EPI and RARE. PET MLEM resolution is 0.87 mm (FWHM) at 5 mm off-center of the FOV and 0.97 mm at 25 mm radial offset. The peaks for true/noise equivalent count rates are 410/240 and 628/486 kcps for the rat and mouse phantoms, and are reached at 30.34/22.85 and 27.94/22.58 MBq. PET image quality is minimally altered by the different MRI sequences. The Bruker PET insert shows no adverse effect on the MRI performance and demonstrated a high sensitivity, sub-millimeter resolution and good image quality even during simultaneous MRI acquisition., We acknowledge the KU Leuven core facility, Molecular Small Animal Imaging Center (MoSAIC), for their support with obtaining scientific data presented in this paper. This work was supported by Stichting tegen Kanker (2015-145, Christophe M. Deroose) and Hercules foundation (AKUL/13/029, Uwe Himmelreich) for the purchase of the PET and MRI equipment respectively. The work was supported by the following funding organizations: European Commission for the PANA project (H2020-NMP-2015-two-stage, grant 686009) and the European ERA-NET project 'CryptoView' (3rd call of the FP7 program Infect-ERA).
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Intraarterial route increases the risk of cerebral lesions after mesenchymal cell administration in animal model of ischemia

  • Argibay González, Bárbara
  • Trekker, Jesse
  • Himmelreich, Uwe
  • Beiras Iglesias, Andrés
  • Topete Camacho, Antonio
  • Taboada Antelo, Pablo
  • Pérez Mato, María
  • Vieites Prado, Alba
  • Iglesias Rey, Ramón
  • Rivas Rey, José
  • Planas, Anna M.
  • Sobrino Moreiras, Tomás
  • Castillo Sánchez, José Antonio
  • Campos Pérez, Francisco
Mesenchymal stem cells (MSCs) are a promising clinical therapy for ischemic stroke. However, critical parameters, such as the most effective administration route, remain unclear. Intravenous (i.v.) and intraarterial (i.a.) delivery routes have yielded varied outcomes across studies, potentially due to the unknown MSCs distribution. We investigated whether MSCs reached the brain following i.a. or i.v. administration after transient cerebral ischemia in rats, and evaluated the therapeutic effects of both routes. MSCs were labeled with dextran-coated superparamagnetic nanoparticles for magnetic resonance imaging (MRI) cell tracking, transmission electron microscopy and immunohistological analysis. MSCs were found in the brain following i.a. but not i.v. administration. However, the i.a. route increased the risk of cerebral lesions and did not improve functional recovery. The i.v. delivery is safe but MCS do not reach the brain tissue, implying that treatment benefits observed for this route are not attributable to brain MCS engrafting after stroke.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Three-Dimensional Hybrid Mesoporous Scaffolds for Simvastatin Sustained Delivery with in Vitro Cell Compatibility

  • Vargas Osorio, Zulema
  • Luzardo Álvarez, Asteria María
  • Piñeiro Redondo, Yolanda
  • Vázquez Vázquez, Carlos
  • Gómez Amoza, José Luis
  • Blanco Méndez, José
  • Otero Espinar, Francisco Javier
  • Rivas Rey, José
The development of scaffolds with suitable physicochemical and mechanical properties allowing for the structural regeneration of injured bone and recovery of the natural biological functionality is still a challenge in the tissue engineering field. Nanostructured materials with added theranostic abilities, together with an interconnected hierarchy of pores, offer the possibility to provide a new generation of bone implants. In this work, scaffolds with highly porous and resistant threedimensional structures have been successfully developed by homogeneously embedding mesoporous silica nanostructures in a bioactive matrix of chitosan/κ-carrageenan. Moreover, magnetite (Fe3O4) nanoparticles were also added to the mesoporous scaffold to include additional magnetic functionalities for diagnostic or therapeutic actions. The complete physicochemical characterization shows mesoporous materials with a wide range of interconnected pores, remarkable surface roughness, and large effective surface area, suitable for cell adhesion. In accordance to these properties, a simvastatin loading and release assay showed high loading capacities and sustained release over a long period of time. Together with a suitable resistance against degradation and biocompatible performance assessed by cell viability assays, these scaffolds show interesting features for delivering drugs with activity in bone regeneration processes.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Multifunctional Superparamagnetic Stiff Nanoreservoirs for Blood Brain Barrier Applications

  • Vargas Osorio, Zulema
  • Silva Candal, Andrés da
  • Piñeiro Redondo, Yolanda
  • Iglesias Rey, Ramón
  • Sobrino Moreiras, Tomás
  • Campos Pérez, Francisco
  • Castillo Sánchez, José Antonio
  • Rivas Rey, José
Neurological diseases (Alzheimer’s disease, Parkinson’s disease, and stroke) are becoming a major concern for health systems in developed countries due to the increment of ageing in the population, and many resources are devoted to the development of new therapies and contrast agents for selective imaging. However, the strong isolation of the brain by the brain blood barrier (BBB) prevents not only the crossing of pathogens, but also a large set of beneficial drugs. Therefore, an alternative strategy is arising based on the anchoring to vascular endothelial cells of nanoplatforms working as delivery reservoirs. In this work, novel injectable mesoporous nanorods, wrapped by a fluorescent magnetic nanoparticles envelope, are proposed as biocompatible reservoirs with an extremely high loading capacity, surface versatility, and optimal morphology for enhanced grafting to vessels during their diffusive flow. Wet chemistry techniques allow for the development of mesoporous silica nanostructures with tailored properties, such as a fluorescent response suitable for optical studies, superparamagnetic behavior for magnetic resonance imaging MRI contrast, and large range ordered porosity for controlled delivery. In this work, fluorescent magnetic mesoporous nanorods were physicochemical characterized and tested in preliminary biological in vitro and in vivo experiments, showing a transversal relaxivitiy of 324.68 mM−1 s −1 , intense fluorescence, large specific surface area (300 m2 g −1 ), and biocompatibility for endothelial cells’ uptake up to 100 µg (in a 80% confluent 1.9 cm2 culture well), with no liver and kidney disability. These magnetic fluorescent nanostructures allow for multimodal MRI/optical imaging, the allocation of therapeutic moieties, and targeting of tissues with specific damage.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Novel synthetic routes of large-pore magnetic mesoporous nanocomposites (SBA-15/Fe3O4) as potential multifunctional theranostic nanodevices

  • Vargas Osorio, Zulema
  • González Gómez, Manuel Antonio
  • Piñeiro Redondo, Yolanda
  • Vázquez Vázquez, Carlos
  • Rodríguez Abreu, Carlos
  • López Quintela, Manuel Arturo
  • Rivas Rey, José
In this paper, novel magnetic silica nanocomposites were prepared by anchoring magnetite nanoparticles onto the outer surface of mesoporous SBA-15 silica; the magnetic nanoparticles were prepared by microemulsion and solvothermal methods, varying the synthesis conditions in order to control the final physicochemical, textural and magnetic properties. The morphology and mesostructure of the materials were characterized by X-ray diffraction (XRD), Fourier-Transform Infrared Spectroscopy (FTIR), N2 adsorption–desorption, and Transmission and Scanning Electron Microscopy (TEM and SEM). Magnetic silica nanocomposites feature a two-dimensional hexagonal arrangement constituted by a homogeneous pore channel system with diameters between 13 and 18 nm and a Brunauer–Emmett–Teller (BET) surface area higher than 260 m2 g−1. The different morphologies of the samples are given by the presence of diverse magnetic nanoparticle arrangements covalently linked onto the outer surface of the mesoporous silica rods. This confers on them a superparamagnetic behaviour with a magnetic response between 50–80 emu g−1, even though the weight percent of magnetite present in the samples does not exceed 21.7%. In addition, the magnetic nanocomposites exhibit magnetic hyperthermia with moderate Specific Absorption Rate (SAR) values
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Alzheimer’s disease seen through the eye: ocular alterations and neurodegeneration

  • Romaus-Sanjurjo, Daniel
  • Regueiro, Uxía 
  • López López, Maite
  • Vázquez Vázquez, Laura
  • Ouro, Alberto
  • Lema Gesto, María Isabel
  • Sobrino, Tomás
Alzheimer’s Disease (AD) is one of the main neurodegenerative diseases worldwide. Unfortunately, AD shares many similarities with other dementias at early stages, which impedes an accurate premortem diagnosis. Therefore, it is urgent to find biomarkers to allow for early diagnosis of the disease. There is increasing scientific evidence highlighting the similarities between the eye and other structures of the CNS, suggesting that knowledge acquired in eye research could be useful for research and diagnosis of AD. For example, the retina and optic nerve are considered part of the central nervous system, and their damage can result in retrograde and anterograde axon degeneration, as well as abnormal protein aggregation. In the anterior eye segment, the aqueous humor and tear film may be comparable to the cerebrospinal fluid. Both fluids are enriched with molecules that can be potential neurodegenerative biomarkers. Indeed, the pathophysiology of AD, characterized by cerebral deposits of amyloid-beta (Aβ) and tau protein, is also present in the eyes of AD patients, besides numerous structural and functional changes observed in the structure of the eyes. Therefore, all this evidence suggests that ocular changes have the potential to be used as either predictive values for AD assessment or as diagnostic tools.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Development of Superparamagnetic Nanoparticles Coated with Polyacrylic Acid and Aluminum Hydroxide as an Efficient Contrast Agent for Multimodal Imaging

  • González Gómez, Manuel Antonio
  • Belderbos, Sarah
  • Yáñez Vilar, Susana
  • Piñeiro Redondo, Yolanda
  • Cleeren, Frederik
  • Bormans, Guy
  • Deroose, Christophe M.
  • Gsell, Willy
  • Himmelreich, Uwe
  • Rivas Rey, José
Early diagnosis of disease and follow-up of therapy is of vital importance for appropriate patient management since it allows rapid treatment, thereby reducing mortality and improving health and quality of life with lower expenditure for health care systems. New approaches include nanomedicine-based diagnosis combined with therapy. Nanoparticles (NPs), as contrast agents for in vivo diagnosis, have the advantage of combining several imaging agents that are visible using different modalities, thereby achieving high spatial resolution, high sensitivity, high specificity, morphological, and functional information. In this work, we present the development of aluminum hydroxide nanostructures embedded with polyacrylic acid (PAA) coated iron oxide superparamagnetic nanoparticles, Fe3O4@Al(OH)3, synthesized by a two-step co-precipitation and forced hydrolysis method, their physicochemical characterization and first biomedical studies as dual magnetic resonance imaging (MRI)/positron emission tomography (PET) contrast agents for cell imaging. The so-prepared NPs are size-controlled, with diameters below 250 nm, completely and homogeneously coated with an Al(OH)3 phase over the magnetite cores, superparamagnetic with high saturation magnetization value (Ms = 63 emu/g-Fe3O4), and porous at the surface with a chemical affinity for fluoride ion adsorption. The suitability as MRI and PET contrast agents was tested showing high transversal relaxivity (r2) (83.6 mM−1 s −1 ) and rapid uptake of 18F-labeled fluoride ions as a PET tracer. The loading stability with 18F-fluoride was tested in longitudinal experiments using water, buffer, and cell culture media. Even though the stability of the 18F-label varied, it remained stable under all conditions. A first in vivo experiment indicates the suitability of Fe3O4@Al(OH)3 nanoparticles as a dual contrast agent for sensitive short-term (PET) and high-resolution long-term imaging (MRI).
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Specific Hippocampal Interneurons Shape Consolidation of Recognition Memory

  • Oliveira da Cruz, Jose F.
  • Busquets García, Arnau
  • Zhao, Zhe
  • Varilh, Marjorie
  • Lavanco, Gianluca
  • Bellocchio, Luigi
  • Robin, Laurie
  • Cannich, Astrid
  • Julio Kalajzić, Francisca
  • Lesté Lasserre, Thierry
  • Maître, Marlène
  • Drago, Filippo
  • Marsicano, Giovanni
  • Soria Gómez, Edgar
A complex array of inhibitory interneurons tightly controls hippocampal activity, but how such diversity specifically affects memory processes is not well understood. We find that a small subclass of type 1 cannabinoid receptor (CB1R)-expressing hippocampal intemeurons determines episodic-like memory consolidation by linking dopamine D-1 receptor (D1R) signaling to GABAergic transmission. Mice lacking CB(1)Rs in D-1-positive cells (D-1-CB1-KO) display impairment in long-term, but not short-term, novel object recognition memory (NOR). Re-expression of CB(1)Rs in hippocampal D1R-positive cells rescues this NOR deficit. Learning induces an enhancement of in vivo hippocampal long-term potentiation (LTP), which is absent in mutant mice. CB1R-mediated NOR and the associated LTP facilitation involve local control of GABAergic inhibition in a D-1-dependent manner. This study reveals that hippocampal CB1R-/D1R-expressing interneurons control NOR memory, identifying a mechanism linking the diversity of hippocampal interneurons to specific behavioral outcomes., We thank Delphine Gonzales, Nathalie Aubailly, and the personnel of the Animal Facilities of the NeuroCentre Magendie for mouse care. We thank the Biochemistry Platform of Bordeaux NeuroCampus and the members of Marsicano's lab for useful discussions. This work was funded by INSERM; the European Research Council (Endofood ERC-2010-StG-260515, CannaPreg ERC-2014-PoC-640923, and MiCaBra ERC-2017-AdG-786467 to G.M.); Fondation pour la Recherche Medicale (FRM; DRM20101220445 to G.M. and DT20160435664 to J.F.O.d.C.); the Human Frontiers Science Program, Region Aquitaine, Agence Nationale de la Recherche (ANR; NeuroNutriSens ANR-13-BSV4-0006, ORUPS ANR-16-CE37-0010-01, and CaCoVi ANR-18-CE160001-02 to G.M.); BRAIN ANR-10-LABX-0043 (to G.M.); NIH/NIDA (1R21DA037678-01); the European Regional Development Fund; the European Union Horizon 2020 Research and Innovation Program (grant agreement 686009); French State/Agence Nationale de la Recherche/IdEx (ANR-10-IDEX-03-02), Eu-Fp7 (FP7-PEOPLE-2013-IEF-623638), and MINECO/AEI (RYC-2017-21776) (to A.B.-G.); FRM (ARF20140129235 to L.B.); and Ikerbasque (The Basque Foundation for Science) and MINECO (Ministerio de Economi ' a y Competitividad) PGC2018-093990-A-I00 (MICIU/AEI/FEDER, UE) (to E.S.-G.).
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Hippocampal neurons require a large pool of glutathione to sustain dendrite integrity and cognitive function

  • Fernandez-Fernandez, Seila
  • Bobo-Jimenez, Veronica
  • Requejo-Aguilar, Raquel
  • Gonzalez-Fernandez, Silvia
  • Resch, Monica
  • Carabias-Carrascoa, Monica
  • Ros Salvador, Joaquim
  • Almeida, Angeles
  • Bolaños, Juan P.
Loss of brain glutathione has been associated with cognitive decline and neuronal death during aging and neurodegenerative diseases. However, whether decreased glutathione precedes or follows neuronal dysfunction has not been unambiguously elucidated. Previous attempts to address this issue were approached by fully eliminating glutathione, a strategy causing abrupt lethality or premature neuronal death that led to multiple interpretations. To overcome this drawback, here we aimed to moderately decrease glutathione content by genetically knocking down the rate-limiting enzyme of glutathione biosynthesis in mouse neurons in vivo. Biochemical and morphological analyses of the brain revealed a modest glutathione decrease and redox stress throughout the hippocampus, although neuronal dendrite disruption and glial activation was confined to the hippocampal CA1 layer. Furthermore, the behavioral characterization exhibited signs consistent with cognitive impairment. These results indicate that the hippocampal neurons require a large pool of glutathione to sustain dendrite integrity and cognitive function., This work was funded by the MINECO, Spain (SAF2016-78114-R to JPB; Red de Excelencia CONSOLREDOX SAF2015-71521-REDC to JPB and JR), H2020 European Commission, Belgium (BatCure Grant 666918 to JPB; PANA grant 686009 to AA), Instituto de Salud Carlos III, Spain (CIBERFES CB16/10/00282 to JPB; PI15/00473 and RD16/ 0019/0018 to AA), Junta de Castilla y León, Spain (IES007P17) and Fundación Ramón Areces, Spain (to AA). This work was funded by FEDER, European Commission, Belgium.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

APC/CCdh1-Rock2 pathway controls dendritic integrity and memory

  • Bobo-Jimenez, Veronica
  • Delgado-Esteban, María
  • Angibaud, Julie
  • Sánchez Morán, Irene
  • Fuente, Antonio de la
  • Yajeya, Javier
  • Nägerl, U. Valentin
  • Castillo, José
  • Bolaños, Juan P.
  • Almeida, Angeles
Disruption of neuronal morphology contributes to the pathology of neurodegenerative disorders such as Alzheimer's disease (AD). However, the underlying molecular mechanisms are unknown. Here, we show that postnatal deletion of Cdh1, a cofactor of the anaphasepromoting complex/cyclosome (APC/C) ubiquitin ligase in neurons [Cdh1 conditional knockout (cKO)], disrupts dendrite arborization and causes dendritic spine and synapse loss in the cortex and hippocampus, concomitant with memory impairment and neurodegeneration, in adult mice. We found that the dendrite destabilizer Rho protein kinase 2 (Rock2), which accumulates in the brain of AD patients, is an APC/C substrate in vivo and that Rock2 protein and activity increased in the cortex and hippocampus of Cdh1 cKO mice. In these animals, inhibition of Rock activity, using the clinically approved drug fasudil, prevented dendritic network disorganization, memory loss, and neurodegeneration. Thus, APC/C-mediated degradation of Rock2 maintains the dendritic network, memory formation, and neuronal survival, suggesting that pharmacological inhibition of aberrantly accumulated Rock2 may be a suitable therapeutic strategy against neurodegeneration., This work was funded by Instituto de Salud Carlos III Grants PI15/00473, BAE14/0005, RD12/0014/0007, and RD16/0019/0018 (to A.A.) and RD12/0014/0001 and RD16/0019/0001 (to J.C.); FEDER (European Regional Development Fund); Ministerio de Economía y Competitividad Grant SAF2016-78114-R (to J.P.B.); and European Union’s Horizon 2020 Research and Innovation Programme Grant 686009 (to A.A. and J.C.). V.B.-J. (PI15/00473) and M.D.-E. (CP0014/00010) are supported by the Instituto de Salud Carlos III. I.S.-M. is supported by the Junta de Castilla y León (Spain)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Intraarterial route increases the risk of cerebral lesions after mesenchymal cell administration in animal model of ischemia

  • Argibay, Bárbara
  • Trekker, Jesse
  • Himmelreich, Uwe
  • Beiras, Andrés
  • Topete, Antonio
  • Taboada, Pablo
  • Pérez-Mato, María
  • Vieites-Prado, Alba
  • Iglesias-Rey, Ramón
  • Rivas, José
  • Planas, Anna M.
  • Sobrino, Tomás
  • Castillo, José
  • Campos, Francisco
Mesenchymal stem cells (MSCs) are a promising clinical therapy for ischemic stroke. However, critical parameters, such as the most effective administration route, remain unclear. Intravenous (i.v.) and intraarterial (i.a.) delivery routes have yielded varied outcomes across studies, potentially due to the unknown MSCs distribution. We investigated whether MSCs reached the brain following i.a. or i.v. administration after transient cerebral ischemia in rats, and evaluated the therapeutic effects of both routes. MSCs were labeled with dextran-coated superparamagnetic nanoparticles for magnetic resonance imaging (MRI) cell tracking, transmission electron microscopy and immunohistological analysis. MSCs were found in the brain following i.a. but not i.v. administration. However, the i.a. route increased the risk of cerebral lesions and did not improve functional recovery. The i.v. delivery is safe but MCS do not reach the brain tissue, implying that treatment benefits observed for this route are not attributable to brain MCS engrafting after stroke., This study has been partially supported by grants from Axencia Galega de Innovación (Xunta de Galicia), the Instituto de Salud Carlos III (PI13/00292; PI14/01879), the Spanish Research Network on Cerebrovascular Diseases RETICS-INVICTUS (RD12/0014), Xunta de Galicia (Consellería Educación GRC2014/027), the European Commission program FEDER and Promoting Active Ageing program: Functional Nanostructures For Alzheimer’s Disease At Ultra-Early Stages” (Pana_686009), a Research and Innovation Project, funded within the EU Horizon 2020 Programme”. Furthermore, this study was also co-funded within the POCTEP (Operational Programme for Cross-border Cooperation Spain-Portugal) program (0681_INVENNTA_1_E), co-financed by the ERDF (European Regional Development Fund). T. Sobrino (CP12/03121) and F. Campos (CP14/00154) are recipients of a research contract from Miguel Servet Program of Instituto de Salud Carlos III. Finally, P. Taboada thanks Mineco and Xunta de Galicia for funding through projects MAT2013-40971-R and EM2013-046, respectively. J Trekker is the recipient of an innovation grant from the IWT-Vlaanderen., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Novel synthetic routes of large-pore magnetic mesoporous nanocomposites (SBA-15/Fe3O4) as potential multifunctional theranostic nanodevices

  • Vargas-Osorio, Zulema
  • Rodríguez-Abreu, Carlos
In this paper, novel magnetic silica nanocomposites were prepared by anchoring magnetite nanoparticles onto the outer surface of mesoporous SBA-15 silica; the magnetic nanoparticles were prepared by microemulsion and solvothermal methods, varying the synthesis conditions in order to control the final physicochemical, textural and magnetic properties. The morphology and mesostructure of the materials were characterized by X-ray diffraction (XRD), Fourier-Transform Infrared Spectroscopy (FTIR), N2 adsorption-desorption, and Transmission and Scanning Electron Microscopy (TEM and SEM). Magnetic silica nanocomposites feature a two-dimensional hexagonal arrangement constituted by a homogeneous pore channel system with diameters between 13 and 18 nm and a Brunauer-Emmett-Teller (BET) surface area higher than 260 m2 g-1. The different morphologies of the samples are given by the presence of diverse magnetic nanoparticle arrangements covalently linked onto the outer surface of the mesoporous silica rods. This confers on them a superparamagnetic behaviour with a magnetic response between 50-80 emu g-1, even though the weight percent of magnetite present in the samples does not exceed 21.7%. In addition, the magnetic nanocomposites exhibit magnetic hyperthermia with moderate Specific Absorption Rate (SAR) values. © 2017 The Royal Society of Chemistry., This work was supported in part by MINECO (Spain) and FEDER Funds (projects MAT 2015-67458-P and CTQ2016-79461-R); and the European Commission (PANA project, Call H2020-NMP-2015-two-stage, Grant 686009; and the MADIA project, Call H2020-ICT-2016-1, Grant 732678)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Amyloid-ß promotes neurotoxicity by Cdk5-induced p53 stabilization

  • Lapresa, Rebeca
  • Agulla, Jesús
  • Sánchez Morán, Irene
  • Zamarreño, Rubén
  • Prieto, Estefanía
  • Bolaños, Juan P.
  • Almeida, Angeles
Neurodegeneration in selective brain areas underlies the pathology of Alzheimer's disease (AD). Although oligomeric amyloid-β (Aβ) plays a central role in the AD pathogenesis, the mechanism of neuronal loss in response to Aβ remains elusive. The p53 tumor suppressor protein, a key regulator of cell apoptosis, has been described to accumulate in affected brain areas from AD patients. However, whether p53 plays any role in AD pathogenesis remains unknown. To address this issue, here we investigated the involvement of p53 on Aß-induced neuronal apoptosis. We found that exposure of neurons to oligomers of the amyloidogenic fragment 25–35 of the Aß peptide (Aβ25-35) promoted p53 protein phosphorylation and stabilization, leading to mitochondrial dysfunction and neuronal apoptosis. To address the underlying mechanism, we focused on cyclin dependent kinase-5 (Cdk5), a known p53-phosphorylating kinase. The results revealed that Aβ25-35 treatment activated Cdk5, and that inhibiting Cdk5 activity prevented p53 protein stabilization. Furthermore, Aβ25-35-mediated mitochondrial dysfunction and neuronal apoptosis were prevented by both genetic and pharmacological inhibition of either p53 or Cdk5 activities. This effect was mimicked with the full-length peptide Aβ1-42. To confirm the mechanism in vivo, Aβ25-35 was stereotaxically injected in the cerebral right ventricle of mice, a treatment that caused p53 protein accumulation, dendrite disruption and neuronal death. Furthermore, these effects were prevented in p53 knockout mice or by pharmacologically inhibiting p53. Thus, Aβ25-35 triggers Cdk5 activation to induce p53 phosphorylation and stabilization, which leads to neuronal damage. Inhibition of the Cdk5-p53 pathway may therefore represent a novel therapeutic strategy against Aβ-induced neurodegeneration., The authors are grateful to Bodegas R. López de Heredia Viña Tondonia for funding part of the work. This work was supported by The Instituto de Salud Carlos III (grant numbers PI15/00473; RD16/0019/0018); European Regional Development Fund; Ministerio de Economía y Competitividad (SAF2016-78114-R); European Union’s Horizon 2020 Research and Innovation Programme (grant agreement 686009); Junta de Castilla y León (grant number IES007P17); and Fundacion Ramon Areces. RL was funded by Ministerio de Educación, Cultura y Deporte (FPU fellowship AP2010-3655). ISM was funded by Junta Castilla y León (EDU/346/2013)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Hippocampal neurons require a large pool of glutathione to sustain dendrite integrity and cognitive function

  • Fernandez-Fernandez, Seila
  • Bobo-Jimenez, Veronica
  • Requejo-Aguilar, Raquel
  • Gonzalez-Fernandez, Silvia
  • Resch-Beusher, Monica
  • Carabias-Carrasco, Mónica
  • Ros, Joaquim
  • Almeida, Angeles
  • Bolaños, Juan P.
Loss of brain glutathione has been associated with cognitive decline and neuronal death during aging and neurodegenerative diseases. However, whether decreased glutathione precedes or follows neuronal dysfunction has not been unambiguously elucidated. Previous attempts to address this issue were approached by fully eliminating glutathione, a strategy causing abrupt lethality or premature neuronal death that led to multiple interpretations. To overcome this drawback, here we aimed to moderately decrease glutathione content by genetically knocking down the rate-limiting enzyme of glutathione biosynthesis in mouse neurons in vivo. Biochemical and morphological analyses of the brain revealed a modest glutathione decrease and redox stress throughout the hippocampus, although neuronal dendrite disruption and glial activation was confined to the hippocampal CA1 layer. Furthermore, the behavioral characterization exhibited signs consistent with cognitive impairment. These results indicate that the hippocampal neurons require a large pool of glutathione to sustain dendrite integrity and cognitive function., This work was funded by the MINECO, Spain (SAF2016-78114-R to JPB; Red de Excelencia CONSOLREDOX SAF2015-71521-REDC to JPB and JR), H2020 European Commission, Belgium (BatCure Grant 666918 to JPB; PANA grant 686009 to AA), Instituto de Salud Carlos III, Spain (CIBERFES CB16/10/00282 to JPB; PI15/00473 and RD16/0019/0018 to AA), Junta de Castilla y León, Spain (IES007P17) and Fundación Ramón Areces, Spain (to AA). This work was funded by FEDER, European Commission, Belgium., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Single-nucleotide polymorphism 309T>G in the MDM2 promoter determines functional outcome after stroke

  • Rodríguez González, Cristina
  • Ramos-Araque, María E.
  • Domínguez-Martínez, Marta
  • Sobrino, Tomás
  • Sánchez Morán, Irene
  • Agulla, Jesús
  • Delgado-Esteban, María
  • Gómez Sánchez, José Carlos
  • Bolaños, Juan P.
  • Castillo, José
  • Almeida, Angeles
[Background and Purpose] The E3 ubiquitin ligase MDM2 (murine double minute 2) is the main negative regulator of the p53 protein—a key player in neuronal apoptosis after ischemia. A functional single-nucleotide polymorphism in the human MDM2 gene promoter (rs2279744) regulates MDM2 protein expression. We investigated whether the MDM2 SNP309, by controlling p53-mediated apoptosis, determines functional outcome after stroke., [Methods] Primary cortical neurons were subjected to oxygen and glucose deprivation. Mice were subjected to ischemic (transient middle cerebral artery occlusion) or hemorrhagic (collagenase injection) stroke models. Protein and mRNA levels of MDM2 and p53 were measured in both neuronal and brain extracts. The interaction of MDM2 with p53 was disrupted by neuronal treatment with nutlin-3a. siRNA was used to knockdown MDM2 expression. We analyzed the link between the MDM2 SNP309 and functional outcome, measured by the modified Rankin Scale scores, in 2 independent hospital-based stroke cohorts: ischemic stroke cohort (408 patients) and intracerebral hemorrhage cohort (128 patients)., [Results] Experimental stroke and oxygen and glucose deprivation induced the expression of MDM2 in the brain and neurons, respectively. Moreover, oxygen and glucose deprivation promoted MDM2 binding with p53 in neurons. Disruption of the MDM2-p53 interaction with nutlin-3a, or MDM2 knockdown by siRNA, triggered p53 accumulation, which increased neuronal susceptibility to oxygen and glucose deprivation-induced apoptosis. Finally, we showed that patients harboring the G allele in the MDM2 promoter had higher MDM2 protein levels and showed better functional outcome after stroke than those harboring the T/T genotype. The T/T genotype was also associated with large infarct volume in ischemic stroke and increased lesion volume in patients with intracerebral hemorrhage., [Conclusions] Our results reveal a novel role for the MDM2-p53 interaction in neuronal apoptosis after ischemia and show that the MDM2 SNP309 determines the functional outcome of patients after stroke., This work was funded by Instituto de Salud Carlos III (PI15/00473, RD16/0019/0018, and RD16/0019/0001), European Regional Development Fund, Ministerio de Economía y Competitividad (SAF2016-78114-R), European Union’s Horizon 2020 Research and Innovation Programme (Grant Agreement 686009), and Junta de Castilla y León (IES007P17). Drs Rodríguez (RD16/0019/0018), Delgado-Esteban (CP0014/00010), and Sobrino (CPII17/00027) are supported by Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

APC/C-Cdh1-Rock2 pathway controls dentritic integrity and memory

  • Bobo-Jimenez, Veronica
  • Delgado-Esteban, María
  • Sánchez Morán, Irene
  • Almeida, Angeles
Trabajo presentado en el 17º Congreso Nacional de la Sociedad Española de Neurociencia, celebrado en Valencia (España), del 27 al 30 de septiembre de 2017, [Background] The correct formation and long-term maintenance of the dendritic network are essential for the normal functioning of the brain. In the adult brain, dendrite stability confers mature neurons the ability to maintain long-term dendritic arbor integrity and integration within networks. Dendritic disruption and loss of dendritic spines and synapses have been reported in neurodegenerative conditions, including Alzheimer’s disease (AD). [Material and methods] We first generated CamKIIalpha-Cre-mediated Cdh1 conditional knockout mice (Cdh1 cKO) for the depletion of Cdh1 in glutamatergic neurons of the cortex and hippocampus from the adult brain. Double-transgenic Cdh1 cKO mice were crossed with Thy1-YFP-H animals, which express yellow fluorescent protein in the pyramidal neurons of the previously mentioned areas. To inhibit Rock activity, fasudil (20 mg/kg body weight; 60 days) was injected intraperitoneally every other day into 30-day-old mice. [Results] Here we show that postnatal deletion of Cdh1, a cofactor of the anaphase promoting complex/cyclosome (APC/C) ubiquitin ligase in neurons (Cdh1 cKO), disrupts dendrite arborization and causes dendritic spine and synapse loss in the cortex and hippocampus, concomitant with memory impairment and neurodegeneration in adult mice. We found that the dendrite destabilizer Rho protein kinase 2 (Rock2), which accumulates in the brain of AD patients, is an APC/CCdh1 substrate in vivo and that Rock2 protein and activity increased in the cortex and hippocampus of Cdh1 cKO mice. In these animals, inhibition of Rock activity, using the clinical approved drug fasudil, prevented dendritic network disorganization, memory loss, and neurodegeneration. [Conclusions] APC/CCdh1-mediated degradation of Rock2 maintains the dendritic network, memory formation, and neuronal survival, suggesting that pharmacological inhibition of aberrantly accumulated Rock2 may be a suitable therapeutic strategy against neurodegeneration., The work was funded by The Instituto de Salud Carlos III (PI15/00473), FEDER (European regional development fund), and European Union’s Horizon 2020 Research and Innovation Programme Grant 686009, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Astrocytic mitochondrial ROS modulate brain metabolism and mouse behaviour

  • Vicente-Gutiérrez, Carlos
  • Bonora, Nicoló
  • Bobo-Jimenez, Veronica
  • Jimenez-Blasco, Daniel
  • López-Fabuel, Irene
  • Fernández, Emilio
  • Josephine, Charlene
  • Bonvento, Gilles
  • Enríquez, José Antonio
  • Almeida, Angeles
  • Bolaños, Juan P.
To satisfy its high energetic demand, the brain depends on the metabolic cooperation of various cell types. For example, astrocytic-derived lactate sustains memory consolidation by serving both as an oxidizable energetic substrate for neurons and as a signalling molecule. Astrocytes and neurons also differ in the regulation of glycolytic enzymes and in the organization of their mitochondrial respiratory chain. Unlike neurons, astrocytes rely on glycolysis for energy generation and, as a consequence, have a loosely assembled mitochondrial respiratory chain that is associated with a higher generation of mitochondrial reactive oxygen species (ROS). However, whether this abundant natural source of mitochondrial ROS in astrocytes fulfils a specific physiological role is unknown. Here we show that astrocytic mitochondrial ROS are physiological regulators of brain metabolism and neuronal function. We generated mice that inducibly overexpress mitochondrial-tagged catalase in astrocytes and show that this overexpression decreases mitochondrial ROS production in these cells during adulthood. Transcriptomic, metabolomic, biochemical, immunohistochemical and behavioural analysis of these mice revealed alterations in brain redox, carbohydrate, lipid and amino acid metabolic pathways associated with altered neuronal function and mouse behaviour. We found that astrocytic mitochondrial ROS regulate glucose utilization via the pentose-phosphate pathway and glutathione metabolism, which modulates the redox status and potentially the survival of neurons. Our data provide further molecular insight into the metabolic cooperation between astrocytes and neurons and demonstrate that mitochondrial ROS are important regulators of organismal physiology in vivo., This work was funded by MINECO (SAF2016-78114-R to J.P.B.), H2020 European Commission (BatCure grant 666918 to J.P.B.) and Fundación BBVA (to J.P.B.). A.A. is funded by H2020 European Commission (PANA grant 686009), Instituto de Salud Carlos III (PI15/00473 and RD16/0019/0018), Junta de Castilla y León (IES007P17) and Fundación Ramón Areces. J.A.E. is funded by MINECO (SAF2015-65633-R). The CNIC is supported by MINECO and Pro-CNIC Foundation, and is a SO-MINECO (award SEV-2015-0505). We thank the viral vector facility headed by A. Bemelmans for producing AAVs at MIRCen. This work was cofunded by FEDER. J.P.B. and J.A.E. are funded by CIBERFES (CB16/10/00282).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting PFKFB3 alleviates cerebral ischemia-reperfusion injury in mice

  • Burmistrova, Olga
  • Olias-Arjona, Ana
  • Lapresa, Rebeca
  • Jimenez-Blasco, Daniel
  • Eremenko, Tatiana
  • Shishov, Dmitry
  • Romanov, Sergei
  • Zakurdaeva, Kristina
  • Almeida, Angeles
  • Fedichev, Peter O.
  • Bolaños, Juan P.
The glycolytic rate in neurons is low in order to allow glucose to be metabolized through the pentose-phosphate pathway (PPP), which regenerates NADPH to preserve the glutathione redox status and survival. This is controlled by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3), the pro-glycolytic enzyme that forms fructose-2,6-bisphosphate, a powerful allosteric activator of 6-phosphofructo-1-kinase. In neurons, PFKFB3 protein is physiologically inactive due to its proteasomal degradation. However, upon an excitotoxic stimuli, PFKFB3 becomes stabilized to activate glycolysis, thus hampering PPP mediated protection of redox status leading to neurodegeneration. Here, we show that selective inhibition of PFKFB3 activity by the small molecule AZ67 prevents the NADPH oxidation, redox stress and apoptotic cell death caused by the activation of glycolysis triggered upon excitotoxic and oxygen-glucose deprivation/reoxygenation models in mouse primary neurons. Furthermore, in vivo administration of AZ67 to mice significantly alleviated the motor discoordination and brain infarct injury in the middle carotid artery occlusion ischemia/reperfusion model. These results show that pharmacological inhibition of PFKFB3 is a suitable neuroprotective therapeutic strategy in excitotoxic-related disorders such as stroke., J.P.B. is funded by the MINECO (SAF2016-78114-R), CIBERFES (CB16/10/00282), H2020 European Commission (BatCure Grant 666918), Ayudas Fundación BBVA a Equipos de Investigación Científica en Biomedicina 2017 and Fundación Ramón Areces. A.A. is funded by H2020 European Commission (PANA grant 686009), Instituto de Salud Carlos III (PI15/00473; RD16/0019/0018) and Fundación Ramón Areces. J.P.B. and A.A. are in part funded by FEDER. This work was part of the “Escalera de Excelencia” program of the Junta de Castilla y León (CLU-2017-03) co-funded by the P.O. FEDER of Castilla y León 14–20.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Glucose metabolism links astroglial mitochondria to cannabinoid effects

  • Jimenez-Blasco, Daniel
  • Busquets-Garcia, Arnau
  • Hebert-Chatelain, Etienne
  • Serrat, Roman
  • Vicente-Gutiérrez, Carlos
  • Ioannidou, Christina
  • Gómez-Sotres, Paula
  • López-Fabuel, Irene
  • Resch-Beusher, Monica
  • Resel, Eva
  • Arnouil, Dorian
  • Saraswat, Dave
  • Varilh, Marjorie
  • Cannich, Astrid
  • Julio-Kalajzic, Francisca
  • Bonilla-Del Río, Itziar
  • Almeida, Angeles
  • Puente, Nagore
  • Achicallende, Svein
  • López-Rodríguez, María L.
  • Jollé, Charlotte
  • Déglon, Nicole
  • Pellerin, Luc
  • Josephine, Charlene
  • Bonvento, Gilles
  • Panatier, Aude
  • Lutz, Beat
  • Piazza, Pier Vincenzo
  • Guzmán, Manuel
  • Bellocchio, Luigi
  • Bouzier-Sore, Anne-Karine
  • Grandes, Pedro
  • Bolaños, Juan P.
  • Marsicano, Giovanni
Astrocytes take up glucose from the bloodstream to provide energy to the brain, thereby allowing neuronal activity and behavioural responses1,2,3,4,5. By contrast, astrocytes are under neuronal control through specific neurotransmitter receptors5,6,7. However, whether the activation of astroglial receptors can directly regulate cellular glucose metabolism to eventually modulate behavioural responses is unclear. Here we show that activation of mouse astroglial type-1 cannabinoid receptors associated with mitochondrial membranes (mtCB1) hampers the metabolism of glucose and the production of lactate in the brain, resulting in altered neuronal functions and, in turn, impaired behavioural responses in social interaction assays. Specifically, activation of astroglial mtCB1 receptors reduces the phosphorylation of the mitochondrial complex I subunit NDUFS4, which decreases the stability and activity of complex I. This leads to a reduction in the generation of reactive oxygen species by astrocytes and affects the glycolytic production of lactate through the hypoxia-inducible factor 1 pathway, eventually resulting in neuronal redox stress and impairment of behavioural responses in social interaction assays. Genetic and pharmacological correction of each of these effects abolishes the effect of cannabinoid treatment on the observed behaviour. These findings suggest that mtCB1 receptor signalling can directly regulate astroglial glucose metabolism to fine-tune neuronal activity and behaviour in mice., This work was funded by: INSERM, the European Research Council (Endofood, ERC–2010–StG–260515 and CannaPreg, ERC-2014-PoC-640923, MiCaBra, ERC-2017-AdG-786467), Fondation pour la Recherche Medicale (FRM, DRM20101220445), the Human Frontiers Science Program, Region Nouvelle Aquitaine and Agence Nationale de la Recherche (ANR; NeuroNutriSens ANR-13-BSV4-0006, CaCoVi ANR 18-CE16-0001-02, MitObesity ANR 18-CE14-0029-01, ORUPS ANR-16-CE37-0010-01 and BRAIN ANR-10-LABX-0043) (to G.M.); NIH/NIDA (1R21DA037678-01), Spanish Ministry of Science, Innovation and Universities (MCINU/FEDER; grants SAF2016-78114-R and RED2018-102576-T), Instituto de Salud Carlos III (CB16/10/00282), an EU BATCure grant (666918), Junta de Castilla y León (Escalera de Excelencia CLU-2017-03), Ayudas Equipos Investigación Biomedicina 2017 Fundación BBVA and Fundación Ramón Areces (to J.P.B.); Instituto de Salud Carlos III (PI18/00285; RD16/0019/0018), the European Regional Development Fund, the European Union’s Horizon 2020 Research and Innovation Programme (grant agreement 686009), Junta de Castilla y León (IES007P17) and Fundación Ramón Areces to (A.A.); French State/ANR/IdEx (ANR-10-IDEX-03-02), Eu-Fp7 (FP7-PEOPLE-2013-IEF-623638) and Ramon y Cajal Investigator Program (RYC-2017-21776) (to A.B.-G.); FRM (SPF20121226369) (to R.S.); FRM (ARF20140129235) (to L.B.); Spanish Ministry of Science, Innovation and Universities (MCINU/FEDER; grants SAF2015-64945-R and RTI2018-095311-B-I00) (to M.G.); Canada Research Chair, Alzheimer Society of Canada—Brain Canada (17-09), Natural Sciences and Engineering Research Council (RGPIN-2015-05880), Canadian Breast Cancer Foundation (2015-317342), Canadian Health Research Institute (CIHR, 388808), New Brunswick Innovation Foundation, New Brunswick Health Research Foundation and Université de Moncton (to E.H.-C.); Basque Government (IT1230-19), Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISC-III), European Regional Development Funds-European Union (ERDF-EU; RD16/0017/0012) and MINECO/FEDER, UE (SAF2015-65034-R) (to P.G.); University of the Basque Country PhD contract (PIF 16/251) (to S.A.); POP contract (BES-2016-076766, BES-C-2016-0051) (to I.B.-D.R.); French State/ANR (ANR-10-IDEX and TRAIL ANR-10-LABX-57); French-Swiss ANR-FNS (ANR-15- CE37-0012) (to A.-K.B.-S.); SFB/TRR 58 ‘Fear, anxiety, anxiety disorders’ (subproject A04); and CRC 1193 ‘Neurobiology of resilience’ (subproject B04) (to B.L.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

APC/C-Cdh1 promotes brain repair after ischemia through the RhoA-ROCK2 pathway

  • Agulla, Jesús
  • Lapresa, Rebeca
  • Almeida, Angeles
Resumen del trabajo presentado al Spanish Society of Biochemistry and Molecular Biology (SEBBM), celebrado en Madrid del 16 al 19 de julio de 2019., Stroke is a leading cause of long-term adult disability and a common cause of death in developed countries. Therefore, it is essential to establish new therapeutic strategies aimed at limiting and/or repairing ischemic neuronal damage. E3 ubiquitin ligase APC/C-Cdh1 is essential for neuronal survival. Previously, we described that Cdh1 regulates the balance between proliferation, neurogenesis and apoptosis. These processes play an essential role in the degeneration/repair balance after ischemic brain damage. Moreover, the cortical reorganization after stroke determines the recovery of the lost brain function. The RhoAROCK2 signalling pathway regulates the morphology, elongation and retraction of neurites, both axons and dendrites, making it an essential pathway in synaptic plasticity. Recently, we demonstrated that Cdh1 regulates the levels and activity of ROCK2 in cortical neurons and modulates the stability of dendrites and synapses. However, whether Cdh1 play a role in stroke remains unknown. To assess this issue, first we used an experimental in vitro model of ischemia/reoxygenation (I/R) and we found that Cdh1 modulates neuronal susceptibility through the RhoA-ROCK2 signalling pathway, since ROCK2 inhibition and knock-down reduced neuronal apoptosis induced by I/R. We also performed a middle cerebral artery occlusion (MCAO) in Cdh1-cKO and WT mice to assess the functional outcome after stroke. We found that Cdh1 is involved in the functional recovery after MCAO, favouring the reduction of infarct volume and the recovery of neurological functions. These results demonstrate that APC/C-Cdh1 actively participates in the neuronal response to I/R damage, enhancing neuronal survival through the RhoA-ROCK2 signalling pathway regulation. Thus, we have identified the Cdh1-ROCK2 axis as a key element in the pathogenesis of stroke and, therefore, as potential molecular targets for stroke treatment., Funded by The Instituto de Salud Carlos III (PI18/00265; RD16/0019/0018); European Regional Development Fund (FEDER); European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement 686009); Junta de Castilla y Leon (IES007P17; Escalera de Excelencia CLU-2017-03 Cofinanciado por el P.O. FEDER de Castilla y Leon 14-20); and Bodegas R. Lopez de Heredia Viña Tondonia., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

P53 orchestrates the inflammatory response in an in vivo model of amyloid-beta-induced neurodegeneration

  • González-Guerrero, Sonia
  • Lapresa, Rebeca
  • Agulla, Jesús
  • Almeida, Angeles
Resumen del trabajo presentado al Spanish Society of Biochemistry and Molecular Biology (SEBBM), celebrado en Madrid del 16 al 19 de julio de 2019., Oligomerization of amyloid- (A ) peptides represents a central event in the etiopathology of Alzheimer's disease. Thus, AB oligomers trigger signalling cascades involving alteration of calcium homeostasis, production of reactive oxygen species, inflammatory processes and mitochondrial dysfunction, culminating in neuronal apoptosis. The basic stationary state of microglia is tolerant, prohomeostatic, and environmental monitoring. Accordingly, to a functional scale, microglial activity can be then categorized into a classical pro-inflammatory and neurotoxic phenotype, known as M1, and the alternative anti-inflammatory M2 phenotype involved in the resolution of inflammation, phagocytosis and tissue repair. Recently, our group have described a role of p53 in neurodegeneration in an experimental model of A -neurotoxicity. In addition to its traditional functions, p53 has recently emerged as a key modulator of the immune response in microglia. Therefore, we hypothesize that p53 could be modulating the activity pro le of the glia in response to AB oligomers. Here we evaluated the function of p53 in the inflammatory response to active A B25-35 oligomers leading to neurodegeneration, and the underlying mechanism. A B25-35 oligomers (9 nmol) were stereotaxically injected in the cerebral right ventricle of mice. We found that oligomerized AB25-35 triggered p53 accumulation leading to an early microglial activation. Besides, we found that p53 favours the characteristic morphological change of activated microglia and dictates the M1/M2 activity pro le. Moreover, the AB injection also increased the number of reactive astrocytes. Altogether, these events lead to dendrite disruption and neuronal death. Furthermore, these effects were prevented by genetic (p53 knockout mice) and pharmacologically (PFT-alpha) inhibition of p53. Our results highlight a key role of p53 in the AB -induced inflammatory response, which may contribute to neurodegeneration., This work was funded by The Instituto de Salud Carlos III (PI18/00265); European Regional Development Fund (FEDER); European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement 686009); and Junta de Castilla y Leon (IES007P17; Escalera de Excelencia CLU-2017-03 Cofi nanciado por el P.O. FEDER de Castilla y Leon 14-20)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Brain neovascularization determines functional recovery after intracerebral hemorrhage through the p53 signaling pathway

  • Rodríguez González, Cristina
  • Carabias-Carrasco, Mónica
  • Resch-Beusher, Monica
  • Prieto, Estefanía
  • Almeida, Angeles
Resumen del trabajo presentado al Spanish Society of Biochemistry and Molecular Biology (SEBBM), celebrado en Madrid del 16 al 19 de julio de 2019., Intracerebral hemorrhage (ICH) is the most severe type of stroke and associates with high mortality rates and risk of disability of affected patients. So far there is no effective treatment, which, added to the lack of accurate prognosis, evidences the need to deepen the mechanisms that regulate brain repair after ICH.We previously shown that the human Tp53 Arg72Pro SNP modulates brain endothelial cells survival after ICH, which is essential for the secretion of growth factors and cytokines (i.e. VEGF) that mediate the mobilization of endothelial progenitor cells (EPCs) from the bone marrow to the peripheral blood. EPCs promote brain vascular repair after ICH, which is a vital response to restore oxygen supply and metabolic substrates in the ischemic brain. Then, pro-apoptotic p53 might be a negative regulator of EPC mobilization, thus affecting the functional prognosis after hemorrhagic stroke. Since p53 is accumulated in the brain after ICH, we speculate that p53 destabilization not only will promote cell survival, but also vascular recovery and brain repair. To con rm this hypothesis, p53 KO mice were subjected to an experimental in vivo model of ICH by injecting bacterial collagenase into the basal ganglia. We also analyzed proliferative markers and perfusion status of newlyformed brain blood vessels in the brain by Evans blue injection. We observed that p53 loss reduced lesion volume and increased levels of circulating EPCs. As a consequence, an improved vascular response was achieved in p53 KO mice, in comparison with those expressing an active p53 protein. Our results point out the impact of the p53 signaling pathway in the balance between brain damage and repair, which conditions functional recovery after ICH, suggesting p53 as a possible therapeutic target for hemorrhagic stroke., This work was funded by ISCIII (PI18/00265; RD16/0019/0018), European Regional Development Fund (FEDER), EU Horizon 2020 Research and Innovation Programme (Grant Agreement 686009), Junta de Castilla y Leon (IES007P17; Escalera de Excelencia CLU-2017-03 Cofinanciado por el P.O. FEDER de Castilla y Leon 14-20)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

WRAP53 fosters DNA repair and neuronal survival after ischemia

  • Sánchez Morán, Irene
  • Rodríguez González, Cristina
  • Almeida, Angeles
Resumen del trabajo presentado al Spanish Society of Biochemistry and Molecular Biology (SEBBM), celebrado en Madrid del 16 al 19 de julio de 2019., Ischemic stroke causes DNA damage in neurons, thereby contributing to cell death unless promptly repaired. An adequate DNA damage response is essential to survive after cerebral ischemia, therefore is indispensable to preserve the integrity of the transcribed genome in post-mitotic neurons; however, the molecular mechanism underlying neuronal survival remains unknown. Here we describe that WRAP53 (WD40 encoding RNA Antisense to p53), a scaffold protein implicated in telomere elongation and DNA repair in tumor cells, also plays an essential role in neuronal survival after ischemia. We observed that ischemia induces oxidative stress and promotes DNA damage, as revealed by the accumulation of yH2AX in neurons. The ischemic insult also promoted a time-dependent increase in Wrap53 gene expression and protein abundance. Remarkably, the ischemic-induced oxidative stress triggers WRAP53 traffic to the nucleus, where WRAP53 is involved in DNA repair processes. By siRNA analysis we confi rm that WRAP53 depletion prevents 53BP1 foci formation, therefore increasing neuronal susceptibility to ischemia-induced apoptosis, whereas WRAP53 expression in ischemic neurons promotes DNA repair events and cell survival. Our results demonstrate the relevance of nuclear accumulation of WRAP53 to maintain genome integrity in neurons and preserve neuronal survival after ischemia., This work was funded by The Instituto de Salud Carlos III (PI18/00265; RD16/0019/0018); European Regional Development Fund (FEDER); European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement 686009); and Junta de Castilla y Leon (IES007P17)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Amyloid-ß promotes neurotoxicity by Cdk5-induced p53 stabilization

  • Lapresa, Rebeca
  • Agulla, Jesús
  • Almeida, Angeles
Resumen del trabajo presentado al Spanish Society of Biochemistry and Molecular Biology (SEBBM), celebrado en Madrid del 16 al 19 de julio de 2019., Neurodegeneration in selective brain areas underlies the pathology of Alzheimer's disease (AD). Although oligomeric amyloid-ß (Aß) plays a central role in the AD pathogenesis, the mechanism of neuronal loss in response to Aß remains elusive. The p53 tumor suppressor protein, a key regulator of cell apoptosis, has been described to accumulate in affected brain areas from AD patients. However, whether p53 plays any role in AD pathogenesis remains unknown. To address this issue, here we investigated the involvement of p53 on Aß-induced neuronal apoptosis. We found that exposure of neurons to oligomers of the amyloidogenic fragment 25-35 of the Aß peptide (Aß 25-35) promoted p53 protein phosphorylation and stabilization, leading to mitochondrial dysfunction and neuronal apoptosis. To address the underlying mechanism, we focused on cyclin dependent kinase-5 (Cdk5), a known p53-phosphorylating kinase. The results revealed that Aß 25-35 treatment activated Cdk5, and that inhibiting Cdk5 activity prevented p53 protein stabilization. Furthermore, Aß 25-35-mediated mitochondrial dysfunction and neuronal apoptosis were prevented by both genetic and pharmacological inhibition of either p53 or Cdk5 activities. This effect was mimicked with the full-length peptide A ß1-42. To confi rm the mechanism in vivo, Aß 25-35 was stereotaxically injected in the cerebral right ventricle of mice, a treatment that caused p53 protein accumulation, dendrite disruption and neuronal death. Furthermore, these effects were prevented in p53 knockout mice or by pharmacologically inhibiting p53. Thus, Aß 25-35 triggers Cdk5 activation to induce p53 phosphorylation and stabilization, which leads to neuronal damage. Inhibition of the Cdk5-p53 pathway may therefore represent a novel therapeutic strategy against Aß -induced neurodegeneration., This work was funded by The Instituto de Salud Carlos III (PI18/00265); European Regional Development Fund (FEDER); European Union's Horizon 2020 Research and Innovation Programme (Grant Agreement 686009); Junta de Castilla y Leon (IES007P17; Escalera de Excelencia CLU-2017-03 Co nanciado por el P.O. FEDER de Castilla y Leon 14-20); and Bodegas R. L opez de Heredia Viña Tondonia., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Preconditioning-Activated AKT Controls Neuronal Tolerance to Ischemia through the MDM2–p53 Pathway

  • Barrio, Emilia
  • Vecino, Rebeca
  • Sánchez Morán, Irene
  • Rodríguez González, Cristina
  • Suarez-Pindado, Alberto
  • Bolaños, Juan P.
  • Almeida, Angeles
  • Delgado-Esteban, María
One of the most important mechanisms of preconditioning-mediated neuroprotection is the attenuation of cell apoptosis, inducing brain tolerance after a subsequent injurious ischemia. In this context, the antiapoptotic PI3K/AKT signaling pathway plays a key role by regulating cell differentiation and survival. Active AKT is known to increase the expression of murine double minute-2 (MDM2), an E3-ubiquitin ligase that destabilizes p53 to promote the survival of cancer cells. In neurons, we recently showed that the MDM2–p53 interaction is potentiated by pharmacological preconditioning, based on subtoxic stimulation of NMDA glutamate receptor, which prevents ischemia-induced neuronal apoptosis. However, whether this mechanism contributes to the neuronal tolerance during ischemic preconditioning (IPC) is unknown. Here, we show that IPC induced PI3K-mediated phosphorylation of AKT at Ser473, which in turn phosphorylated MDM2 at Ser166. This phosphorylation triggered the nuclear stabilization of MDM2, leading to p53 destabilization, thus preventing neuronal apoptosis upon an ischemic insult. Inhibition of the PI3K/AKT pathway with wortmannin or by AKT silencing induced the accumulation of cytosolic MDM2, abrogating IPC-induced neuroprotection. Thus, IPC enhances the activation of PI3K/AKT signaling pathway and promotes neuronal tolerance by controlling the MDM2–p53 interaction. Our findings provide a new mechanistic pathway involved in IPC-induced neuroprotection via modulation of AKT signaling, suggesting that AKT is a potential therapeutic target against ischemic injury., This research was funded by the Instituto de Salud Carlos III (PI18/00103 to M.D.-E.; PI18/00285 and RD16/0019/0018 to A.A.; CB16/10/00282 to J.P.B.), MICINN (PID2019-105699RB-I00/AEI/10.13039/501100011033 and RED2018-102576-T to J.P.B.; SAF2017-90794-REDT to A.A.), Junta de Castilla y León (Escalera de Excelencia CLU-2017-03; CSI151P20), Ayudas Equipos Investigación Biomedicina 2017 Fundación BBVA (to J.P.B.), Fundación Ramón Areces (to A.A.P. and J.P.B.), European Regional Development Fund, and European Union’s Horizon 2020 Research and Innovation Program (Grant Agreement 686009 to A.A.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Abrogating mitochondrial ROS in neurons or astrocytes reveals cell-specific impact on mouse behaviour

  • Vicente-Gutiérrez, Carlos
  • Bonora, Nicoló
  • Jimenez-Blasco, Daniel
  • López-Fabuel, Irene
  • Bates, Georgina
  • Murphy, Michael P.
  • Almeida, Angeles
  • Bolaños, Juan P.
Cells naturally produce mitochondrial reactive oxygen species (mROS), but the in vivo pathophysiological significance has long remained controversial. Within the brain, astrocyte-derived mROS physiologically regulate behaviour and are produced at one order of magnitude faster than in neurons. However, whether neuronal mROS abundance differentially impacts on behaviour is unknown. To address this, we engineered genetically modified mice to down modulate mROS levels in neurons in vivo. Whilst no alterations in motor coordination were observed by down modulating mROS in neurons under healthy conditions, it prevented the motor dis- coordination caused by the pro-oxidant neurotoxin, 3-nitropropionic acid (3-NP). In contrast, abrogation of mROS in astrocytes showed no beneficial effect against the 3-NP insult. These data indicate that the impact of modifying mROS production on mouse behaviour critically depends on the specific cell-type where they are generated., J.P.B. is funded by the Agencia Estatal de Investigación (SAF2016-78114-R, PID2019-105699RB-I00/AEI/10.13039/501100011033 and RED2018-102576-T), Plan Nacional sobre Drogas (2020I028), ISCIII (CB16/10/00282), Junta de Castilla y León (Escalera de Excelencia CLU-2017-03), Ayudas Equipos Investigación Bio-medicina 2017 Fundación BBVA and Fundación Ramón Areces. A.A. is unded by the ISCIII (PI18/00265, RD16/0019/0018), AEI (PI18/00265, RD16/0019/0018) and European Union’s Horizon 2020 Research and Innovation Program (Grant Agreement 686009). J.P.B. and A.A. are fundedby the grant CSI151P20 from the Junta de Castilla y Leon., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Impact of p53 on the microglial response in an in vivo model of amyloid-beta-induced neurodegeneration

  • González Sánchez, Sergio
  • Lapresa, Rebeca
  • Agulla, Jesús
  • Almeida, Angeles
Resumen del trabajo presentado en el 43rd Annual Meeting of the Spanish Society of Biochemistry & Molecular Biology, celebrado en Barcelona, del 19 al 22 de julio de 2021, Alzheimer’s disease (AD) is a neurodegenerative disorder characterised by the presence of amyloid-β (Aβ) and Tau protein aggregates. Although research has classically focused on neuronal alterations, neuroinflammation has emerged as a key factor in AD pathophysiology. The main cellular components involved in the brain inflammatory process are glial cells. Aβ aggregates bind to pattern recognition receptors on microglia and astrocytes, whichtriggers an immune response that contributes to disease progres sion1,2. Functionally, microglia can be classified into M1 proinflammatory/neurotoxic or M2 anti-inflammatory/neuroprotective phenotypes 2. Previously, we described a key role for p53 in Aβ-induced neurodegeneration in vivo3. Recently, p53 has emerged as a modulator of the immune response in microglia4. Here, we evaluated the possible role of p53 as a modulator of the microglial response to Aβ25-35, leading to neurodegeneration., Funds: Instituto de Salud Carlos III (PI18/00265;RD16/0019/0018); FEDER; European Union’s Horizon2020 Research and Innovation Programme (GA 686009);Junta de Castilla y León (PhD grant co-financed by Fondo Social Europeo. EDU/601/2020)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

P53 orchestrates the microglial response upon amyloid-beta-induced neurodegeneration in vivo

  • González-Guerrero, Sonia
  • Lapresa, Rebeca
  • Agulla, Jesús
  • Almeida, Angeles
Trabajo presentado al 15th International Conference AD/PD 2021 celebrada de forma virtual del 9 al 14 de marzo de 2021, Amyloid-β (Aβ) oligomers trigger signalling cascades involving alteration of calcium homeostasis, ROS production, inflammatory processes and mitochondrial dysfunction, culminating in neuronal apoptosis. According to a functional scale, microglia can be categorized into the classical pro-inflammatory/neurotoxic phenotype, known as M1, and an alternative anti-inflammatory/neuroprotective M2 phenotype, which is involved in the resolution of inflammation, phagocytosis and tissue repair. Previously, we described a key role of p53 in neurodegeneration induced by Aβ neurotoxicity in vivo. Recently, p53 has emerged as a key modulator of the immune response in microglia. Here we evaluated whether p53 is modulating the microglial response to Aβ25-35 oligomers leading to neurodegeneration, Funded by The Instituto de Salud Carlos III (PI18/00265); European Union’s Horizon 2020 Research and Innovation Programme (Grant Agreement 686009) and Programa Operativo FSE Castilla y León 2014-2020.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

ROS-induced Sp1 regulates Wrap53 levels and nuclear accumulation leading to neuroprotection after ischemia

  • Martínez-Peralta, S.
  • Sánchez Morán, Irene
  • Rodríguez González, Cristina
  • Almeida, Angeles
Resumen del trabajo presentado en el 19 Congreso Nacional de la SENC celebrado en Lleida del 3 al 5 de noviembre de 2021, Ischemia-induced oxidative stress compromises genome integrity, which results in DNA damage and neuronal loss after stroke. We described that reactive oxygen species (ROS) generated during ischemia upregulate WRAP53 (WD40 encoding RNA antisense to p53) and trigger its translocation to the nucleus, where it promotes DNA repair [1]. However, the molecular mechanism remains unknown. Transcription factor Sp1 acts as a pleiotropic oxidative stress response protein in neurons. Particularly, ROS-induced Sp1 expression promotes neuroprotection against ischemia [2].i nterestingly, Wrap53 promoter contains putative consensus sequences (GC boxes) for Sp1. We analyze the role of Sp1 as a modulating factor of WRAP53-mediated neuronal survival and its impact on brain repair after stroke., Funded:ISCIII (FI19/00160;PI18/00265;RD16/0019/0018), FEDER, EU Horizon 2020 Research and Innovation Programme (Grant Agreement 686009), Junta de Castilla y León (CSI151P20;Escalera de Excelencia CLU-2017-03 Cofinanciado por P.O.FEDER de Castilla y León 14-20)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Targeting mitochondrial p53 as a novel therapeutic approach for the treatment of Alzheimer`s Disease

  • Lapresa, Rebeca
  • Agulla, Jesús
  • Almeida, Angeles
Trabajo presentado ene el 15th International Conference AD/PD 2021, celerado on line del 9 al 14 de marzo de 2021, [Aims] Alzheimer’s disease (AD) is a complex multifactorial disease in which neural death occurs predominantly by apoptosis. The p53 protein functions as a key regulator of apoptosis and accumulates in brains from AD patients. This protein naturally occurs in humans in two functional polymorphic variants, resulting in Arg or Pro at residue 72, which regulates p53 apoptotic activity. Here we evaluate the relevance of the p53 Arg72Pro single nucleotide polymorphism (SNP) in Amyloid-β(Aβ)-induced neurotoxicity both in vitro and in vivo., [Methods] We used primary cortical neurons from humanized Tp53 Arg72Pro knock-in mice treated with Aβ oligomers (10 μM) and an Aβ (5 nmol) intracerebroventricular injection model in Tp53 Arg72Pro knock-in mice to assess mitochondrial function, neurodegeneration and cognitive status., [Results] We found that the Arg genotype increased neuronal susceptibility to Aβ toxicity upon p53 mitochondrial stabilization in vitro. Accordingly, Arg72 mice were more susceptible to Aβ- induced neurodegeneration and memory loss than Pro72 mice. Interestingly, treatment with PFTμ (40 mgKg-1), a small molecule that inhibits p53 mitochondrial binding without affecting its transactivation activity, prevented Aβ-induced memory deficit in Arg72 mice, [Conclusions] Our results demonstrate that blocking the p53-mitochondria interaction prevents cognitive decline in Aβ-injected mice. Moreover, PFTμ may be useful to develop novel therapeutic approaches for AD, especially in patients carrying the Arg72 SNP variant, Funded by Instituto de Salud Carlos III (PI18/00265; RD16/0019/0018); FEDER; European Union’s Horizon 2020 Research and Innovation Programme (Grant Agreement 686009) and Junta de Castilla y León (Escalera de Excelencia (CLU-2017-03 Cofinanciado por el P.O. FEDER de Castilla y León).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Abrogating mitochondrial ROS in neurons or astrocytes reveals cell-specific impact on mouse behaviour

  • Vicente-Gutiérrez, Carlos
  • Bonora, Nicoló
  • Jimenez-Blasco, Daniel
  • López-Fabuel, Irene
  • Bates, Georgina
  • Murphy, Michael P.
  • Almeida, Angeles
Cells naturally produce mitochondrial reactive oxygen species (mROS), but the in vivo pathophysiological significance has long remained controversial. Within the brain, astrocyte-derived mROS physiologically regulate behaviour and are produced at one order of magnitude faster than in neurons. However, whether neuronal mROS abundance differentially impacts on behaviour is unknown. To address this, we engineered genetically modified mice to down modulate mROS levels in neurons in vivo. Whilst no alterations in motor coordination were observed by down modulating mROS in neurons under healthy conditions, it prevented the motor discoordination caused by the pro-oxidant neurotoxin, 3-nitropropionic acid (3-NP). In contrast, abrogation of mROS in astrocytes showed no beneficial effect against the 3-NP insult. These data indicate that the impact of modifying mROS production on mouse behaviour critically depends on the specific cell-type where they are generated., J.P.B. is funded by the Agencia Estatal de Investigación (SAF2016-78114-R, PID2019-105699RB-I00/AEI/10.13039/501100011033 and RED2018-102576-T), Plan Nacional sobre Drogas (2020I028), ISCIII (CB16/10/00282), Junta de Castilla y Le ́on (Escalera de Excelencia CLU-2017-03), Ayudas Equipos Investigación Biomedicina 2017 Fundaci ́on BBVA and Fundaci ́on Ram ́on Areces. A.A. is funded by the ISCIII (PI18/00265, RD16/0019/0018), AEI (SAF2017-90794-REDT) and European Union’s Horizon 2020 Research and Innovation Program (Grant Agreement 686009). J.P.B. and A.A. are funded by the grant CSI151P20 from the Junta de Castilla y Leon.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Aberrant upregulation of the glycolytic enzyme PFKFB3 in CLN7 neuronal ceroid lipofuscinosis

  • López-Fabuel, Irene
  • García-Macia, Marina
  • Buondelmonte, Constantina
  • Burmistrova, Olga
  • Bonora, Nicoló
  • Alonso-Batán, Paula
  • Morant Ferrando, Brenda
  • Vicente-Gutiérrez, Carlos
  • Jimenez-Blasco, Daniel
  • Quintana-Cabrera, Ruben
  • Fernández, Emilio
  • Llop Roig, Jordi
  • Ramos-Cabrer, Pedro
  • Sharaireh, Aseel
  • Guevara-Ferrer, Marta
  • Fitzpatrick, Lorna M.
  • Thompton, Christopher D.
  • McKay, Tristan R.
  • Storch, Stephan
  • Medina, Diego L.
  • Mole, Sara E
  • Fedichev, Peter O.
  • Almeida, Angeles
  • Bolaños, Juan P.
CLN7 neuronal ceroid lipofuscinosis is an inherited lysosomal storage neurodegenerative disease highly prevalent in children. CLN7/MFSD8 gene encodes a lysosomal membrane glycoprotein, but the biochemical processes affected by CLN7-loss of function are unexplored thus preventing development of potential treatments. Here, we found, in the Cln7∆ex2 mouse model of CLN7 disease, that failure in autophagy causes accumulation of structurally and bioenergetically impaired neuronal mitochondria. In vivo genetic approach reveals elevated mitochondrial reactive oxygen species (mROS) in Cln7∆ex2 neurons that mediates glycolytic enzyme PFKFB3 activation and contributes to CLN7 pathogenesis. Mechanistically, mROS sustains a signaling cascade leading to protein stabilization of PFKFB3, normally unstable in healthy neurons. Administration of the highly selective PFKFB3 inhibitor AZ67 in Cln7∆ex2 mouse brain in vivo and in CLN7 patients-derived cells rectifies key disease hallmarks. Thus, aberrant upregulation of the glycolytic enzyme PFKFB3 in neurons may contribute to CLN7 pathogenesis and targeting PFKFB3 could alleviate this and other lysosomal storage diseases., This work was funded by the European Regional Development Fund, European Union’s Horizon 2020 Research and Innovation Programme (BATCure grant No. 666918 to J.P.B., S.E.M., D.L.M., S.S., and T.R.M.; PANA grant No. 686009 to A.A.), Agencia Estatal de Investigación (PID2019-105699RB-I00/AEI/10.13039/501100011033 and RED2018‐102576‐T to J.P.B.; SAF2017-90794-REDT to A.A.), Instituto de Salud Carlos III (CB16/10/00282 to J.P.B.; PI18/00285; RD16/0019/0018 to A.A.), Junta de Castilla y León (CS/151P20 and Escalera de Excelencia CLU-2017-03 to J.P.B. and A.A.), Ayudas Equipos Investigación Biomedicina 2017 Fundación BBVA (to J.P.B.), and Fundación Ramón Areces (to J.P.B. and A.A.). SM benefits from MRC funding to the MRC Laboratory for Molecular Cell Biology University Unit at UCL (award code MC_U12266B) towards lab and office space. Part of this work was funded by Gero Discovery L.L.C. M.G.M. is an ISCIII-Sara Borrel contract recipient (CD18/00203).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Amyloid-β Induces Cdh1-Mediated Rock2 Stabilization Causing Neurodegeneration

  • Lapresa, Rebeca
  • Agulla, Jesús
  • González-Guerrero, Sonia
  • Bolaños, Juan P.
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline, which is causally related to the accumulation of abnormally folded amyloid-β (Aβ) peptide and hyperphosphorylated tau protein aggregates. The dendritic spine regulator Rho protein kinase 2 (Rock2) accumulates in the brain at the earliest stages of AD and remains increased during disease progression. However, the molecular mechanism that upregulates Rock2 in AD, and its role in the disease progression, are unknown. Here, we found that oligomers of the amyloidogenic fragment 25–35 of the Aβ peptide (Aβ25-35) trigger Rock2 accumulation and activation in mouse cortical neurons in primary culture and in mouse hippocampus in vivo. Neuronal apoptotic death and memory impairment caused by Aβ25-35 administration were rescued by genetic and pharmacological inhibition of Rock2 activity. Mechanistically, Aβ25-35 elicited cyclin dependent kinase-5 (Cdk5)-mediated phosphorylation of Cdh1, a cofactor that is essential for the activity of the E3 ubiquitin ligase anaphase-promoting complex/cyclosome (APC/C) in neurons. Notably, phosphorylated Cdh1 was disassembled from the APC/C complex, causing its inactivation and subsequent Rock2 protein stabilization and activation. Moreover, Aβ25-35-induced neuronal apoptosis was prevented by expressing a phosphodefective form of Cdh1, but not by a phosphomimetic Cdh1. Finally, Cdh1 inactivation, using both genetic and pharmacological approaches, enhanced Aβ25-35-mediated neuronal death through a mechanism that was prevented by inhibition of Rock2 activity. These results indicate that the Cdk5-Cdh1 signaling pathway accounts for the increased Rock2 activity by amyloidogenic Aβ peptides and that this mechanism may contribute to neurodegeneration and memory loss in AD., The work was funded by The Instituto de Salud Carlos III (to AA, PI21/00727 and RD21/0006/0005); European Regional Development Fund; European Union’s Horizon 2020 Research and Innovation Programme (to AA, grant agreement 686009); and Junta de Castilla y León (to AA and JB, CSI151P20 and CLU201703 P.O.FEDER CyL1420), and the Agencia Estatal de Investigación (to JB, PID 2019-105699RB-I00, MCIN/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR). RL, JA and SG-G are funded by Junta de Castilla y León (to RL and JA, CSI151P20; to SG-G, EDU/601/2020).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Oxidative stress-triggered nuclear WRAP53 translocation promotes neuronal survival and functional recovery after stroke

  • Sánchez Morán, Irene
  • Rodríguez González, Cristina
  • Bolaños, Juan P.
  • Almeida, Angeles
Trabajo presentado en la 20th Biennial Meeting of The Society for Free Radical Research International (SFRR-I) celebrada online del 15 al 18 de marzo de 2021, Ischemic stroke is the leading cause of neurologic death and long-term adult disability worldwide. Ischemia-induced oxidative stress compromises genome integrity, resulting in DNA damage. Failure of neurons to efficiently repair DNA double-strands breaks (DSB) contributes to cerebral damage and impairs functional recovery after stroke. However, the molecular machinery that regulates DNA repair in this neurological disorder remains unknown. Here we describe that WRAP53 (WD40 encoding RNA Antisense to p53), a scaffold protein implicated in telomere elongation and DNA repair in tumor cells, plays an essential role in neuronal survival after ischemia. We found that experimental ischemia, performed by oxygen and glucose deprivation (OGD), promoted oxidative stress-induced DSB in neurons. These events spatiotemporally correlated with WRAP53 upregulation and nuclear translocation to activate DSBs repair response. Mechanistically, OGD triggered a burst in reactive oxygen species that induced both DSB and translocation of WRAP53 to the nucleus to promote DNA repair, a pathway that was confirmed in an in vivo mouse model of stroke. Noticeably, nuclear translocation of WRAP53 occurred faster in OGD neurons expressing the Wrap53 human nonsynonymous single-nucleotide polymorphism (SNP) rs2287499 (c.202C>G). Patients carrying this SNP showed less infarct volume and better functional outcome after stroke. These results provide a new signaling role for reactive oxygen species in the mechanism of DSB repair in neurons and unravel the role of WRAP53 to maintaining genome integrity and survival after stroke., This work was funded by the Instituto de Salud Carlos III (PI18/00265 and RD16/0019/0018), European Regional Development Fund (FEDER), Ministerio de Ciencia en Innovación (SAF2017-90794-REDT), European Union’s Horizon 2020 Research and Innovation Programme (grant agreement 686009), Junta de Castilla y León (IES007P17 and Escalera de Excelencia CLU-2017-03 Cofinanciado por el P.O. FEDER de Castilla y León), and Fundación Ramón Areces.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Intracerebroventricular phospho-tau immunotherapy alleviates cortical phospho-tau burden and motor phenotype in a neuron-specific P301S tauopathy mouse

  • Kemppainen, S.
  • Aramburu-Núñez, M.
  • Koivisto, H.
  • Posado-Fernández, A.
  • Felix-Garcia, M. R.
  • Nurminen, K.
  • Häkli, S.
  • Abelli-Deulofeu, E.
  • Kaisto, M.
  • Custodia, A.
  • van Olst, L.
  • Willman, R-M
  • Mäkinen, P.
  • Miettinen, P. O.
  • Schouten, M.
  • Iglesias-Rey, Ramón
  • Kamermans, A.
  • Martiskainen, H.
  • Rauramaa, T.
  • de Vries, H. E.
  • Eng, E.
  • Salo, R.
  • Kettunen, M.
  • Gröhn, O.
  • Gureviciene, I.
  • Chmielevski, P.
  • Ouro, A.
  • Lapresa, Rebeca
  • Agulla, Jesús
  • Almeida, Angeles
  • Doria, G.
  • Flores, O.
  • Aguiar, P.
  • Carmans, S.
  • Roucourt, B.
  • Hiltunen, M.
  • Sobrino, T.
  • Tanila, H.
Pathological tau accumulation disrupts neuronal function, leading to neurodegeneration and dementia in tauopathies, such as Alzheimer's disease and frontotemporal dementia. Despite the progression of several anti-tau therapies to clinical trials, no disease-modifying treatments for tauopathies exist. Tau hyperphosphorylation is a key factor in pathology progression. Among all tau phosphorylation sites targeted in preclinical passive immunization studies, the classic AT8 pathological tau phosphorylation sites have remained understudied. Thus, we investigated the potential of immunotherapy against phosphorylated tau (pTau) in a P301S mouse model of tauopathy. We administered a new monoclonal B6 antibody that targets tau phosphorylation sites at serine 202, threonine 205 and serine 208 either systemically for 3 months or locally into the cerebral ventricles for 1 or 2 months via an osmotic minipump. Systemic administration failed to reach the brain effectively, and subsequently, was not able to alleviate the progressive motor impairment seen in this tauopathy mouse model. By contrast, intraventricular administration improved motor function in earlier stages of pathology but had a lesser effect in later stages. The local administration for 8 weeks reduced the number of pTau positive neurons in cortex and hippocampus. Our findings indicate that targeting the classical pathological tau phosphorylation sites can ameliorate tau pathology and improve function in a mouse tauopathy model. These results add to growing evidence supporting the efforts in developing tau-targeting immunotherapies for neurodegenerative diseases associated with pathological tau deposits., This research was funded by the European Union, Horizon 2020 project PANA, grant number 686009, Academy of Finland (grant numbers 338182, 307866, 315459, and 330178, 339767); the Sigrid Jusélius Foundation (SJ-2022) and the Strategic Neuroscience Funding of the University of Eastern Finland (NEURO-RC-2019). A.P-F.'s grant was funded by the European Union's FP7 Marie-Curie Initial Training Network program (grant agreement 606950). This study was also funded by grants from the Xunta de Galicia (IN607A2022/07), Instituto de Salud Carlos III (ISCIII) (PI22/00938, PI21/00727, CIBERNED CB22/05/00067, and RD21/0006/0005) and Ministerio de Ciencia e Innovación (RTC2019-007373-1 and PDC2022-134000-I00). Furthermore, this study was also supported by grants from the INTERREG Atlantic Area (EAPA_791/2018_NEUROATLANTIC project), INTER-REG V A España Portugal (POCTEP) (0624_2IQBIONEURO_6_E), and the European Regional Development Fund (ERDF). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Characterization of a preclinical PET insert in a 7 tesla MRI scanner: beyond NEMA testing

  • Gsell, Willy
  • Molinos, César
  • Correcher, Carlos
  • Belderbos, Sarah
  • Wouters, Jens
  • Junge, Sven
  • Heidenreich, Michael
  • Velde, Greetje Vande
  • Rezaei, Ahmadreza
  • Nuyts, Johan
  • Cawthorne, Christopher
  • Cleeren, Frederik
  • Nannan, Lise
  • Deroose, Christophe M.
  • Himmelreich, Uwe
  • González Martínez, Antonio Javier
This study evaluates the performance of the Bruker positron emission tomograph (PET) insert combined with a BioSpec 70/30 USR magnetic resonance imaging (MRI) scanner using the manufacturer acceptance protocol and the NEMA NU 4–2008 for small animal PET. The PET insert is made of 3 rings of 8 monolithic LYSO crystals (50 × 50 × 10 mm3) coupled to silicon photomultipliers (SiPM) arrays, conferring an axial and transaxial FOV of 15 cm and 8 cm. The MRI performance was evaluated with and without the insert for the following radiofrequency noise, magnetic field homogeneity and image quality. For the PET performance, we extended the NEMA protocol featuring system sensitivity, count rates, spatial resolution and image quality to homogeneity and accuracy for quantification using several MRI sequences (RARE, FLASH, EPI and UTE). The PET insert does not show any adverse effect on the MRI performances. The MR field homogeneity is well preserved (Diameter Spherical Volume, for 20 mm of 1.98 ± 4.78 without and −0.96 ± 5.16 Hz with the PET insert). The PET insert has no major effect on the radiofrequency field. The signal-to-noise ratio measurements also do not show major differences. Image ghosting is well within the manufacturer specifications (<2.5%) and no RF noise is visible. Maximum sensitivity of the PET insert is 11.0% at the center of the FOV even with simultaneous acquisition of EPI and RARE. PET MLEM resolution is 0.87 mm (FWHM) at 5 mm off-center of the FOV and 0.97 mm at 25 mm radial offset. The peaks for true/noise equivalent count rates are 410/240 and 628/486 kcps for the rat and mouse phantoms, and are reached at 30.34/22.85 and 27.94/22.58 MBq. PET image quality is minimally altered by the different MRI sequences. The Bruker PET insert shows no adverse effect on the MRI performance and demonstrated a high sensitivity, sub-millimeter resolution and good image quality even during simultaneous MRI acquisition., This work was supported by Stichting tegen Kanker (2015-145, Christophe M. Deroose) and Hercules foundation (AKUL/13/029, Uwe Himmelreich) for the purchase of the PET and MRI equipment respectively. The work was supported by the following funding organizations: European Commission for the PANA project (H2020-NMP-2015-two-stage, grant 686009) and the European ERA-NET project ‘CryptoView’ (3rd call of the FP7 program Infect-ERA)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Hippocampal neurons require a large pool of glutathione to sustain dendrite integrity and cognitive function

  • Fernandez-Fernandez, Seila
  • Bobo-Jimenez, Veronica
  • Requejo-Aguilar, Raquel
  • Gonzalez-Fernandez, Silvia
  • Resch, Monica
  • Carabias-Carrascoa, Monica
  • Ros Salvador, Joaquim
  • Almeida, Angeles
  • Bolaños, Juan P.
Loss of brain glutathione has been associated with cognitive decline and neuronal death during aging and neurodegenerative diseases. However, whether decreased glutathione precedes or follows neuronal dysfunction has not been unambiguously elucidated. Previous attempts to address this issue were approached by fully eliminating glutathione, a strategy causing abrupt lethality or premature neuronal death that led to multiple interpretations. To overcome this drawback, here we aimed to moderately decrease glutathione content by genetically knocking down the rate-limiting enzyme of glutathione biosynthesis in mouse neurons in vivo. Biochemical and morphological analyses of the brain revealed a modest glutathione decrease and redox stress throughout the hippocampus, although neuronal dendrite disruption and glial activation was confined to the hippocampal CA1 layer. Furthermore, the behavioral characterization exhibited signs consistent with cognitive impairment. These results indicate that the hippocampal neurons require a large pool of glutathione to sustain dendrite integrity and cognitive function., This work was funded by the MINECO, Spain (SAF2016-78114-R to JPB; Red de Excelencia CONSOLREDOX SAF2015-71521-REDC to JPB and JR), H2020 European Commission, Belgium (BatCure Grant 666918 to JPB; PANA grant 686009 to AA), Instituto de Salud Carlos III, Spain (CIBERFES CB16/10/00282 to JPB; PI15/00473 and RD16/ 0019/0018 to AA), Junta de Castilla y León, Spain (IES007P17) and Fundación Ramón Areces, Spain (to AA). This work was funded by FEDER, European Commission, Belgium.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Specific hippocampal interneurons shape consolidation of recognition memory

  • Oliveira da Cruz, Jose F.
  • Busquets Garcia, Arnau, 1985-
  • Zhao, Zhe
  • Varilh, Marjorie
  • Lavanco, Gianluca
  • Robin, Laurie
  • Cannich, Astrid
  • Julio-Kalajzić, Francisca
  • Lesté-Lasserre, Thierry
  • Maître, Marlène
  • Drago, Filippo
  • Marsicano, Giovanni
  • Soria-Gómez, Edgar
A complex array of inhibitory interneurons tightly controls hippocampal activity, but how such diversity specifically affects memory processes is not well understood. We find that a small subclass of type 1 cannabinoid receptor (CB1R)-expressing hippocampal interneurons determines episodic-like memory consolidation by linking dopamine D1 receptor (D1R) signaling to GABAergic transmission. Mice lacking CB1Rs in D1-positive cells (D1-CB1-KO) display impairment in long-term, but not short-term, novel object recognition memory (NOR). Re-expression of CB1Rs in hippocampal D1R-positive cells rescues this NOR deficit. Learning induces an enhancement of in vivo hippocampal long-term potentiation (LTP), which is absent in mutant mice. CB1R-mediated NOR and the associated LTP facilitation involve local control of GABAergic inhibition in a D1-dependent manner. This study reveals that hippocampal CB1R-/D1R-expressing interneurons control NOR memory, identifying a mechanism linking the diversity of hippocampal interneurons to specific behavioral outcomes., We thank Delphine Gonzales, Nathalie Aubailly, and the personnel of the Animal Facilities of the NeuroCentre Magendie for mouse care. We thank the Biochemistry Platform of Bordeaux NeuroCampus and the members of Marsicano’s lab for useful discussions. This work was funded by INSERM; the European Research Council (Endofood ERC-2010-StG-260515, CannaPreg ERC-2014-PoC-640923, and MiCaBra ERC-2017-AdG-786467 to G.M.); Fondation pour la Recherche Medicale (FRM; DRM20101220445 to G.M. and DT20160435664 to J.F.O.d.C.); the Human Frontiers Science Program, Region Aquitaine, Agence Nationale de la Recherche (ANR; NeuroNutriSens ANR-13-BSV4-0006, ORUPS ANR-16-CE37-0010-01, and CaCoVi ANR-18-CE16-0001-02 to G.M.); BRAIN ANR-10-LABX-0043 (to G.M.); NIH/NIDA (1R21DA037678-01); the European Regional Development Fund; the European Union Horizon 2020 Research and Innovation Program (grant agreement 686009); French State/Agence Nationale de la Recherche/IdEx (ANR-10-IDEX-03-02), Eu-Fp7 (FP7-PEOPLE-2013-IEF-623638), and MINECO/AEI (RYC-2017-21776) (to A.B.-G.); FRM (ARF20140129235 to L.B.); and Ikerbasque (The Basque Foundation for Science) and MINECO (Ministerio de Economía y Competitividad) PGC2018-093990-A-I00 (MICIU/AEI/FEDER, UE) (to E.S.-G.).